ロード中...
Pazopanib in advanced soft tissue sarcomas
Pazopanib is the first and only tyrosine kinase inhibitor currently approved for the treatment of multiple histological subtypes of soft tissue sarcoma (STS). Initially developed as a small molecule inhibitor of vascular endothelial growth factor receptors, preclinical work indicates that pazopanib...
保存先:
| 出版年: | Signal Transduct Target Ther |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Publishing Group UK
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6522548/ https://ncbi.nlm.nih.gov/pubmed/31123606 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41392-019-0049-6 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|